Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Jim Pankovich"'
Autor:
Stephen Sundquist, Gerald Batist, Kathy Brodeur-Robb, Kathryn Dyck, Bernhard J. Eigl, David K. Lee, Jaqueline Limoges, Holly Longstaff, Jim Pankovich, Anna Sadura, Patrick Sullivan, Janet E. Dancey
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 3857-3865 (2021)
Canada’s vast geography, and centralized delivery of cancer care and clinical trials create barriers for trial participation for patients in remote and rural settings. The development and implementation of a framework that enables safe and regulato
Externí odkaz:
https://doaj.org/article/8a1ef9f8529040d5a5f614026d3da060
Autor:
Daniel S. Labach, Hinissan P. Kohio, Edwin A. Tse, Ermela Paparisto, Nicole J. Friesen, Jim Pankovich, Mark Bazett, Stephen D. Barr
Publikováno v:
Biomolecules, Vol 13, Iss 7, p 1095 (2023)
The COVID-19 pandemic has highlighted an urgent need to discover and test new drugs to treat patients. Metal-based drugs are known to interact with DNA and/or a variety of proteins such as enzymes and transcription factors, some of which have been sh
Externí odkaz:
https://doaj.org/article/1f8ebd3fc6334736b72bd1fc2cc4d4d5
Autor:
Simon Sutcliffe, Shirin Kalyan, Jim Pankovich, Jenny M. H. Chen, Rashieda Gluck, Darby Thompson, Momir Bosiljcic, Mark Bazett, Richard N. Fedorak, Remo Panaccione, Jeffrey Axler, John K. Marshall, David W. Mullins, Boyko Kabakchiev, Dermot P. B. McGovern, Julie Jang, Andrew Coldman, Gillian Vandermeirsch, Brian Bressler, Hal Gunn
Publikováno v:
Frontiers in Medicine, Vol 6 (2019)
Background: Current Crohn's disease (CD) therapies focus on suppressing immune function and come with consequent risk, such as infection and cancer. Notwithstanding, most CD patients still experience disease progression. There is a need for new CD tr
Externí odkaz:
https://doaj.org/article/16ebca018dc54a3db4c12643872ffe03
Autor:
Ho Pan Sham, Mark Bazett, Momir Bosiljcic, Hyungjun Yang, Beryl Luk, Hong T. Law, Vijay Morampudi, Hong B. Yu, Jim Pankovich, Simon Sutcliffe, Brian Bressler, John K. Marshall, Richard N. Fedorak, Jenny Chen, Michelle Jones, Hal Gunn, Shirin Kalyan, Bruce A. Vallance
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Background: Current ulcerative colitis (UC) treatments are focused on symptom management primarily via immune suppression. Despite the current arsenal of immunosuppressant treatments, the majority of patients with UC still experience disease progress
Externí odkaz:
https://doaj.org/article/60605729c3b44b1cbbdab2ced5054902
Autor:
Mark Bazett, Amanda M. Costa, Momir Bosiljcic, Rebecca M. Anderson, Matthew P. Alexander, Stephanie W. Y. Wong, Salim Dhanji, Jenny MH Chen, Jim Pankovich, Stephen Lam, Simon Sutcliffe, Hal Gunn, Shirin Kalyan, David W. Mullins
Publikováno v:
OncoImmunology, Vol 7, Iss 3 (2018)
Acute infection is known to induce strong anti-tumor immune responses, but clinical translation has been hindered by the lack of an effective strategy to safely and consistently provoke a therapeutic response. These limitations are overcome with a no
Externí odkaz:
https://doaj.org/article/edc987a804c9426cbb1774284128f680
Autor:
Barr, Daniel S. Labach, Hinissan P. Kohio, Edwin A. Tse, Ermela Paparisto, Nicole J. Friesen, Jim Pankovich, Mark Bazett, Stephen D.
Publikováno v:
Biomolecules; Volume 13; Issue 7; Pages: 1095
The COVID-19 pandemic has highlighted an urgent need to discover and test new drugs to treat patients. Metal-based drugs are known to interact with DNA and/or a variety of proteins such as enzymes and transcription factors, some of which have been sh
Publikováno v:
Cancers; Volume 15; Issue 1; Pages: 28
BOLD-100 (sodium trans-[tetrachlorobis(1H indazole)ruthenate(III)]) is a ruthenium-based anticancer compound currently in clinical development. The identification of cancer types that show increased sensitivity towards BOLD-100 can lead to improved d
Autor:
Janet Dancey, Holly Longstaff, Gerald Batist, Jim Pankovich, David K Lee, Kathy Brodeur-Robb, Bernhard J Eigl, Anna Sadura, Stephen Sundquist, Patrick S. Sullivan, Jaqueline Limoges, Kathryn Dyck
Publikováno v:
Current Oncology
Current Oncology, Vol 28, Iss 329, Pp 3857-3865 (2021)
Current Oncology, Vol 28, Iss 329, Pp 3857-3865 (2021)
Canada’s vast geography, and centralized delivery of cancer care and clinical trials create barriers for trial participation for patients in remote and rural settings. The development and implementation of a framework that enables safe and regulato
Autor:
Jennifer Spratlin, Grainne O'Kane, Do-Youn Oh, Sun Young Rha, Elaine McWhirter, Elena Elimova, Petr Kavan, Moon Ki Choi, Dae Won Kim, Rachel Goodwin, J Randolph Hecht, Seung Tae Kim, Dong-Hoe Koo, Khalif Halani, E Russell McAllister, Michelle Jones, Malcolm Snow, Yasmin Lemmerick, Gonzalo Spera, Jim Pankovich
Publikováno v:
Cancer Research. 83:CT149-CT149
Background: BOLD-100 is a first-in-class ruthenium-based anticancer agent in Phase 1b/2a clinical development for the treatment of advanced gastrointestinal (GI) cancers in combination with FOLFOX. BOLD-100 demonstrated synergy in established preclin
Publikováno v:
Cancer Research. 83:2259-2259
Proven metallotherapeutics, such as cisplatin and oxaliplatin, alter immune responses as part of their multimodal mechanisms-of-action. These immune responses can drive efficacy in specific patient populations and/or in combination with other oncolog